Apogee Shares Up Nearly 100% in 12 Months, and This $62 Million Buy Signals Ongoing Conviction

2026-02-22 14:16:14 ET

On February 17, 2026, Perceptive Advisors disclosed a buy of 978,662 shares of Apogee Therapeutics (NASDAQ:APGE) , with an estimated transaction value of $61.64 million based on quarterly average pricing.

According to a February 17, 2026, SEC filing , Perceptive Advisors increased its stake in Apogee Therapeutics (NASDAQ:APGE) by 978,662 shares. The estimated transaction value was $61.64 million, based on the average share price during the fourth quarter of 2025. The fund ended the quarter holding 2,330,651 shares, with the value of the position rising by $122.20 million, reflecting both new purchases and share price appreciation.

Apogee Therapeutics, Inc. is a biotechnology company specializing in the development of extended half-life monoclonal antibodies for the treatment of atopic dermatitis and chronic obstructive pulmonary disease. The company leverages a pipeline of differentiated biologic candidates designed to address significant unmet needs in immunology. Apogee's strategy focuses on advancing its clinical programs to commercialization, aiming to establish a competitive position in targeted therapeutic markets.

Continue reading